Neurol. pro Praxi, 2004; 5: 291-294

Význam časné léčby roztroušené sklerózy mozkomíšní

Eva Havrdová
Centrum pro demyelinizační onemocnění Neurologická klinika 1. LF UK a VFN Praha

Keywords: roztroušená skleróza, časná léčba, interferon beta, glatiramer acetát, neuroprotekce.

Published: December 31, 2004  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Havrdová E. Význam časné léčby roztroušené sklerózy mozkomíšní. Neurol. praxi. 2004;7(5):291-294.

Roztroušená skleróza (RS) je závažné autoimunitní onemocnění centrálního nervového systému, postihující a invalidizující především mladé jedince. V patogenezi se uplatňují jednak mechanizmy autoimunitního zánětu, jednak mechanizmy neurodegenerace. Jejich maximum se odehrává v prvých letech nemoci, kdy je pacient zdánlivě klinicky v dobrém stavu, což donedávna svádělo k představě, že s dlouhodobou léčbou není třeba spěchat. Ukázalo se však, že pouze imunomodulační léčba, zavedená v co nejčasnějším stadiu, má šanci zpomalit vývoj onemocnění a nevratné invalidity a je třeba ji prosadit u co největšího počtu pacientů, aby se zmírnil dopad této zákeřné choroby. Zároveň je nutno najít nejvhodnější neuroprotektivní léky, aby se zabránilo nadměrné ztrátě centrálních axonů.

Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Babbe H, Roers A, Waisman A. Clonal expansions of CD8+ T-cells dominate the T-cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction. J Exp Med 2000; 192: 393-404. Go to original source... Go to PubMed...
    2. Battistini L, Piccio L, Rossi B, et al. CD8+ T cells from patients with acute multiple sclerosis display selective increase of adhesiveness in brain venules: a critical role for P-selectin glycoprotein ligand-1. Blood 2003 Jun 15; 101(12): 4775-4782. Go to original source... Go to PubMed...
    3. Bo L, Vedeler CA, Nyland HI, Trapp BD, Mork SJ. Subpial demyelination in the cerebral cortex of multiple sclerosis patients. J Neuropathol Exp Neurol 2003 Jul; 62(7): 723-732. Go to original source... Go to PubMed...
    4. Comi G, Filippi M, Barkhof F, et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 2001 May 19; 357(9268): 1576-1582. Go to original source... Go to PubMed...
    5. De Stefano N, Narayan S, Francis GS, et al. Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability. Arch Neurol 2001; 58: 65-70. Go to original source... Go to PubMed...
    6. Filippi M, Rovaris M, Rocca MA, et al. Glatiramer acetate reduces the proportion of new MS lesions envolving into, ,black holes". Neurology 2001; 57: 731-733. Go to original source... Go to PubMed...
    7. Gold BG, Voda J, Yu X, McKeon G, Bourdette DN. FK506 and a nonimmunosuppressant derivative reduce axonal and myelin damage in experimental autoimmune encephalomyelitis: Neuroimmunophilin ligand-mediated neuroprotection in a model of multiple sclerosis. J Neurosci Res 2004; 77(3): 367-377. Go to original source... Go to PubMed...
    8. Jacobs LD, Beck RW, Simon JH, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 2000 Sep 28; 343(13): 898-904. Go to original source... Go to PubMed...
    9. Kornek B, Storch MK, Bauer J, et al. Distribution of a calcium channel subunit in dystrophic axons in multiple sclerosis and experimental autoimmune encephalomyelitis. Brain 2001; 124: 1114-1124. Go to original source... Go to PubMed...
    10. Lassmann H, Bruck W, Lucchinetti C. Heterogenity of multiple sclerosis pathogenesis: implications for diagnosis and therapy. Trends Mol Med 2001 Mar; 7(3): 115-121. Go to original source... Go to PubMed...
    11. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50(1): 121-127. Go to original source... Go to PubMed...
    12. Medana I, Martinic MA, Wekerle H, Neumann H. Transection of major histocompatibility complex class I - induced neuritis by cytotoxic T lymphocytes. Am J Pathol 2001; 159: 809-815. Go to original source... Go to PubMed...
    13. Nitsch R, Pohl EE, Smorodchenko A, et al. Direct impact of T cells on neurons revealed by two-photon microscopy in living brain tissue. J Neurosci 2004; 24(10): 2458-2464. Go to original source... Go to PubMed...
    14. Pitt D, Nagelmeier IE, Wilson HC, Raine CS. Glutamate uptake by oligodendrocytes: Implications for excitotoxicity in multiple sclerosis. Neurology 2003 Oct 28; 61(8): 1113-1120. Go to original source... Go to PubMed...
    15. Takahashi JL, Giuliani F, Power C et al. Interleukin-1beta promotes oligodendrocyte death through glutamate excitotoxicity. Ann Neurol 2003 May; 53(5): 588-595. Go to original source... Go to PubMed...
    16. Trapp BD, Peterson J, Ransoff RM, et al. Axonal transection in lesion of multiple sclerosis. N Engl J Med 1998; 338: 278-285. Go to original source... Go to PubMed...
    17. Tubridy N, Behan PO, Capildeo R, et al. The effect of anti-alpha4 integrin antibody on brain lesion activity in MS. The UK Antegren Study Group. Neurology 1999 Aug 11; 53(3): 466-472. Go to original source... Go to PubMed...

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.